Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL28213702 | 0.94 | OTC (0.38) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL20678185 | 0.94 | PTGS1 (0.41) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL29191149 | 0.94 | OTC (0.41) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27757867 | 0.90 | GSR (0.43) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL28528502 | 0.90 | GSR (0.47) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1278091 | 0.89 | PTGS1 (0.41) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL22360939 | 0.89 | PTGS1 (0.41) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL909965 | 0.89 | PTGS1 (0.41) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL20678167 | 0.89 | PTGS1 (0.46) | OTCPTGS1SLC7A11DDAH1NOS2 | |
| Arginine SCHEMBL16637167 | 0.89 | PTGS1 (0.46) | OTCPTGS1SLC7A11DDAH1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019877-A1 | HYDROGEL PARTICLE ENCAPSULATION AND SUSPENSION MEDIA REMOVAL | CellDrop Biosciences, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240026088-A1 | Hydrogel Particle Encapsulation and Suspension Media Removal | CellDrop Biosciences, Inc. | 2024-01-25 | — | — | US | disclosed |
| WO-2024020426-A2 | HYDROGEL PARTICLE ENCAPSULATION AND SUSPENSION MEDIA REMOVAL FOR IN VIVO REGENERATIVE TREATMENT | CellDrop Biosciences, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240024364-A1 | Hydrogel Particle Encapsulation and Suspension Media Removal for In Vivo Regenerative Treatment | CellDrop Biosciences, Inc. | 2024-01-25 | — | — | US | disclosed |
| US-10407537-B2 | Integrated zwitterionic conjugated polymers for bioelectronics, biosensing, regenerative medicine, and energy applications | THE UNIVERSITY OF AKRON (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170327635-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | THE UNIVERSITY OF AKRON (US) | 2017-11-16 | — | — | US | disclosed |
| US-9695275-B2 | Integrated zwitterionic conjugated polymers for bioelectronics, biosensing, regenerative medicine, and energy applications | THE UNIVERSITY OF AKRON (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160244554-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | THE UNIVERSITY OF AKRON | 2016-08-25 | — | — | US | disclosed |
| WO-2015054484-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | THE UNIVERSITY OF AKRON (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407537-B2 | Integrated zwitterionic conjugated polymers for bioelectronics, biosensing, regenerative medicine, and energy applications | PCCA, PHOSPHO1, PC | OTC 3505/4885PTGS1 2148/4885SLC7A11 755/4885 |
| US-20170327635-A1 | INTEGRATED ZWITTERIONIC CONJUGATED POLYMERS FOR BIOELECTRONICS, BIOSENSING, REGENERATIVE MEDICINE, AND ENERGY APPLICATIONS | PCCA, PHOSPHO1, PC | OTC 3505/4885PTGS1 2148/4885SLC7A11 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.